Currently, there are 69.64M common shares owned by the public and among those 37.92M shares have been available to trade.
The company’s stock has a 5-day price change of 109.88% and 76.28% over the past three months. PHAT shares are trading 9.85% year to date (YTD), with the 12-month market performance down to -13.90% lower. It has a 12-month low price of $2.21 and touched a high of $19.71 over the same period. PHAT has an average intraday trading volume of 1.64 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 107.45%, 107.49%, and -3.25% respectively.
Institutional ownership of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) shares accounts for 57.92% of the company’s 69.64M shares outstanding.
It has a market capitalization of $622.74M and a beta (3y monthly) value of 0.09. The earnings-per-share (ttm) stands at -$5.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 32.32% over the week and 16.22% over the month.
Analysts forecast that Phathom Pharmaceuticals Inc (PHAT) will achieve an EPS of -0.88 for the current quarter, -0.55 for the next quarter and -0.47 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -1.11 while analysts give the company a high EPS estimate of -1.11. Comparatively, EPS for the current quarter was -1.25 a year ago. Earnings per share for the fiscal year are expected to increase by 42.60%, and 89.46% over the next financial year.
Looking at the support for the PHAT, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on February 14, 2025, with the firm’s price target at $23. Stifel coverage for the Phathom Pharmaceuticals Inc (PHAT) stock in a research note released on May 03, 2024 offered a Buy rating with a price target of $24. Needham was of a view on January 05, 2024 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on August 09, 2023, issuing a price target of $28. Evercore ISI on their part issued Outperform rating on May 11, 2023.
